ClinicalTrials.gg
CompletedNCT04484337Updated May 29, 2026Results posted

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

A Phase 1 interventional study of Cabotegravir sodium (Oral Lead In) and Cabotegravir 400 mg/mL in HIV Infections, sponsored by ViiV Healthcare. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
22nd of 36
138 · median 200
Started
2020
with 5 others
Phase 1
10 of 36
none open now
Registered
21st of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 22nd largest by enrollment, is one of 6 that started in 2020, is one of 10 in phase 1, and was the 21st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This is an active control, randomized study to investigate the safety, tolerability and PK of repeat dose administration of long-acting CAB 400 mg/mL formulation intramuscular (IM) (gluteus medius and vastus lateralis) and subcutaneous (SC) (abdominal) injections in healthy adult participants.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • Long-Acting Injection
  • Pharmacokinetics
  • Safety
  • Tolerability
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 50 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation.
  • A participant with a clinical abnormality or laboratory parameters which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included if the investigator determines and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Participants who are negative on two consecutive tests for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), performed at Screening and within 5 days of admission to the Phase I unit, using an approved molecular test (Polymerase chain reaction [PCR]).
  • Body weight more than or equal to (>=)40 kilogram (kg) and (BMI) within the range 18 to 32 kilogram per square meter (kg/m\^2).
  • Male participants are eligible to participate if they agree to use methods and refrain from donating sperm.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of less than (\<)1 percent(%).
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Signs and symptoms which in the opinion of the investigator are suggestive of Coronavirus disease 2019 (COVID-19) (that is [i.e.] fever, cough etc) within 14 days of inpatient admission.
  • Contact with known COVID-19 positive person/s in the 14 days prior to inpatient admission.
  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Abnormal blood pressure as determined by the investigator.
  • (ALT) more than (>)1.5 times (ULN).
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • interval (QTc) >450 milliseconds (msec).
  • A known to hyaluronidases (Cohort 4h only).
  • The participant has an underlying skin disease or disorder (infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) that would interfere with assessment of injection sites.
  • Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (less than or equal to [\<=]325 mg) or hereditary coagulation and disorders such as hemophilia or Von Willebrand Disease.
  • Participants considered to have insufficient musculature to allow safe administration of CAB 400 mg/mL (gluteus medius or vastus lateralis).
  • History of ongoing or seizure disorder within the previous 2 years, including participants who have required treatment for seizures within this time period.
  • History of or on-going high-risk behaviors that may put the participant at increased risk for (HIV) acquisition in the opinion of the investigator. This includes participants in HIV discordant relationships, or men who report current or prior unprotected anal sex with other men and those reporting prior or current injecting drug use.
  • Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the product (whichever is longer).
  • Participation in the study would result in loss of blood or blood products in excess of 500 mL within 56 days.
  • The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Presence of surface antigen (HBsAg), or positive antibody test result at screening or within 3 months prior to first dose of study treatment.
  • A positive pre-study drug/alcohol screen.
  • Exclusion criteria for screening (ECG):

    1. Heart rate: For Males \<45 or >100 beats per minute (bpm), for females \<50 or >100 bpm.
    2. PR Interval: For males and females \<120 or >220 msec.
    3. QRS duration: For males and females \<70 or >120 msec.
    4. QT duration corrected for heart rate by Fridericia's formula (QTcF) interval: For males and females >450 msec.
  • Evidence of previous myocardial infarction.
  • Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular [AV] block [2nd degree or higher], Wolff-Parkinson-White [WPW] syndrome).
  • Sinus Pauses >3 seconds.
  • Any significant arrhythmia which, in the opinion of the Investigator or GlaxoSmithKline (GSK)/ViiV Medical monitor, will interfere with the safety for the individual participant.
  • Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats).
  • Positive HIV antibody/antigen test. Participants will be advised regarding safer sex. In the event a participant acquires HIV during the course of the study they will be required to withdraw from the study and will be referred urgently to an HIV treatment center for further management.
  • Regular use of known drugs of abuse.
  • Regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.
  • Participants with a history of intolerance to or with to the use of topical non-steroidal anti-inflammatory drugs (NSAIDs) or topical will be excluded from participation in Cohort 4b.
  • Regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of >14 units for males or >7 units for females.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6 months prior to screening.
  • The participant has a tattoo or other dermatological condition overlying the location of injection or a prior history of silicone implants (gluteal) which may interfere with interpretation of injection site reactions or administration of CAB LA.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Oral Cabotegravir (CAB) 30

    Participants received oral dose of CAB 30 milligram (mg) tablet once daily for Days 1 to 28 in the oral lead in phase.

    Drug: Cabotegravir sodium (Oral Lead In)

  • Experimental
    Part 1: Cohort 1 (C1) CAB 400

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 400 milligram per milliliter (mg/mL) (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the gluteus medius, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL

  • Active comparator
    Part 1: Cohort 1 (C1) CAB200

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the gluteus medius, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL

  • Experimental
    Part 1: Cohort 2 (C2) CAB400

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 400 milligram per milliliter (mg/mL) (Injection 1: 600 mg and Injection 2: 400 mg respectively) subcutaneously in the abdomen, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL

  • Active comparator
    Part 1: Cohort 2 (C2) CAB200

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 300 mg and Injection 2: 200 mg respectively) subcutaneously in the abdomen, 4 weeks apart, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL

  • Experimental
    Part 1: Cohort 3 (C3) CAB400

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 400 milligram per milliliter (mg/mL) (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the lateral thigh, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL

  • Active comparator
    Part 1: Cohort 3 (C3) CAB200

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 600 mg and Injection 2: 400 mg respectively) intramuscularly in the lateral thigh, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL

  • Experimental
    Part 1: Cohort 4 (C4) CAB400

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB400 mg/mL (Injection 1: 400 mg and Injection 2: 200 mg respectively) at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase, with the first injection in the gluteus medius intramuscularly and the second subcutaneously.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL

  • Active comparator
    Part 1: Cohort 4 (C4) CAB200

    Following receipt of oral CAB 30 in the OLI phase, participants received two injections of CAB 200 mg/mL (Injection 1: 400 mg and Injection 2: 100 mg respectively) at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase, with the first injection in the gluteus medius intramuscularly and the second subcutaneously.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL

  • Experimental
    Part 1: Cohort 4b Group 1 (C4b G1)

    Following receipt of oral CAB 30 in the OLI phase, all participants received two injections of 300 mg of CAB 400 mg/mL subcutaneously, at Day 1 of Injection Phase and approximately at Week 4 of Injection Phase, The participants received a topical non-steroidal anti-inflammatory drug (NSAID) and topical steroid placebo with Injection 1, a topical steroid and NSAID placebo with Injection 2.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL · Drug: Topical Non-steroidal anti-inflammatory drug (NSAID) · Drug: Topical steroid · Drug: Topical NSAID placebo · Drug: Topical steroid placebo

  • Experimental
    Part 1: Cohort 4b Group 2 (C4b G2)

    Following receipt of oral CAB 30 in the OLI phase, all participants received two injections of 300 mg of CAB 400 mg/mL subcutaneously 4 weeks apart. The participants received a topical steroid and NSAID placebo with injection 1, NSAID and topical steroid placebo with injection 2.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL · Drug: Topical Non-steroidal anti-inflammatory drug (NSAID) · Drug: Topical steroid · Drug: Topical NSAID placebo · Drug: Topical steroid placebo

  • Experimental
    Part 1: Cohort 4h (C4h) CAB400 + rHuPH20

    Following receipt of oral CAB 30 in the OLI phase, participants received one subcutaneous injection of 400 mg of CAB 400 mg/mL along with 5000 units (U) of recombinant human hyaluronidase PH20 (rHuPH20) sequentially.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Experimental
    Part 1: Cohort 4h (C4h) CAB200 + rHuPH20

    Following receipt of oral CAB 30 in the OLI phase, participants received one subcutaneous injection of 400 mg of CAB 200 mg/mL along with 5000 U of rHuPH20 sequentially.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Experimental
    Part 2: Cohort 5 (C5) CAB400

    Following receipt of oral CAB 30 in the OLI phase, participants received two intramuscular gluteal injections of 800 mg of CAB 400 mg/mL approximately 12 weeks apart.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 400 mg/mL

  • Active comparator
    Part 2: Cohort 5 (C5) CAB200

    Following receipt of oral CAB 30 in the OLI phase, participants received two intramuscular gluteal injections of 400 mg of CAB 200 mg/mL approximately 12 weeks apart. The dose was matched to the volume of CAB 400 mg/mL administered earlier in the same cohort.

    Drug: Cabotegravir sodium (Oral Lead In) · Drug: Cabotegravir 200 mg/mL

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 Injection 1: Time of Maximum Observed Plasma Concentration (Tmax) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h

    Blood samples were collected for Pharmacokinetic (PK) analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 1 - Day 1 to Week 4

  2. Part 1 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b

    Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Day 1 to Week 52 follow-up

  3. Part 2 Injection 1: Tmax for CAB 400 mg/ml Formulation for Cohort 5

    Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 1 - Day 1 to Week 12

  4. Part 2 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohort 5

    Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Day 1 to Week 52 follow-up

  5. Part 1 Injection 2: Apparent Terminal Phase Half-life (T1/2) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b

    Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Week 4 to Week 52 follow-up

  6. Part 2 Injection 2: T1/2 for CAB 400 mg/ml Formulation for Cohort 5

    Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Week 12 to Week 52 follow-up

  7. Part 1 Injection 2: Terminal Absorption Elimination Rate Constant (KALA) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b

    KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Week 4 to Week 52 follow-up

  8. Part 2 Injection 2: KALA for CAB 400 mg/ml Formulation for Cohort 5

    KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Week 12 to Week 52 follow-up

  9. Part 1 Injection 1: Plasma Trough Concentrations (Ctau) of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h

    Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.

    Time frame: Injection 1 - Day 1 to Week 4

  10. Part 1 Injection 2: Ctau of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b

    Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.

    Time frame: Injection 2 - Day 1 to Week 4

  11. Part 2 Injection 1: Ctau of CAB 400 mg/ml Formulation for Cohort 5

    Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. Ctau is the trough concentration at the end of the dosing interval. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 800mg was presented. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR and ECLAIRE studies.

    Time frame: Injection 1 - Day 1 to Week 12

  12. Part 1 Injection 1: Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC(0-t)) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h

    Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 1 - Day 1 to Week 4

  13. Part 1 Injection 2: AUC(0-t) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4 and 4b

    Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Day 1 to Week 4

  14. Part 1 Injection 1: Maximum Observed Plasma Concentration (Cmax) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h

    The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 1 - Day 1 to Week 4

  15. Part 1 Injection 2: Cmax of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b

    The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

    Time frame: Injection 2 - Day 1 to Week 4

Secondary outcomes

  1. Part 1 and Part 2: Number of Participants With Adverse Events (AEs) in Injection Phase and Follow up Phase

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.

    Time frame: From Injection 1 day 1 up to 52 weeks follow-up

  2. Part 1 and Part 2: Number of Participants With Liver Biochemistry Abnormalities in Injection Phase and Follow up Phase

    Blood samples were collected at indicated timepoints to analyze the liver biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Bilirubin and Direct Bilirubin. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.

    Time frame: From Injection 1 day 1 up to 52 weeks follow-up

  3. Cmax for CAB Following Oral 30 mg Administration

    Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.

    Time frame: Up to Day 29

  4. Tmax for CAB Following Oral 30 mg Administration

    Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.

    Time frame: Up to Day 29

  5. AUC(0-t) for CAB Following Oral 30 mg Administration

    Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.

    Time frame: Up to Day 29

  6. Concentration at 24 Hours (C24) for CAB Following Oral 30 mg Administration

    Time frame: At 24 hours

  7. Ctau for CAB Following Oral 30 mg Administration

    Time frame: Up to 24 hours on day 29 (Oral lead in phase)

  8. Cmax of CAB 200 for Cohort 4h

    Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.

    Time frame: Injection 1 - Day 1 to Week 52 follow-up

  9. Tmax of CAB 200 for Cohort 4h

    Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.

    Time frame: Injection 1 - Day 1 to Week 52 follow-up

  10. AUC(0-t) of CAB 200 for Cohort 4h

    Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.

    Time frame: Injection 1 - Day 1 to Week 52 follow-up

  11. Ctau of CAB 200 for Cohort 4h and in ATLAS/FLAIR Study

    Blood samples were collected for PK analysis of CAB after subcutaneous administration. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 400mg was presented.

    Time frame: Injection 1 - Day 1 to Week 52 follow-up

  12. T1/2 of CAB 200 & CAB 400 for Cohort 4h

    Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.

    Time frame: Injection 1 - Day 1 to Week 52 follow-up

  13. KALA of CAB 200 & CAB 400 for Cohort 4h

    KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.

    Time frame: Injection 1 - Day 1 to Week 52 follow-up

07

Results

Posted May 29, 2026

Participant flow

Oral Lead In (OLI) Phase
Participant flow — Oral Lead In (OLI) Phase
MilestoneOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Started13800000000000000
Not randomized to injection phase1300000000000000
Randomized to injection phase12500000000000000
Withdrawn from study after randomization and before receiving an injection800000000000000
Completed11700000000000000
Not completed2100000000000000
Withdrew: Withdrawal by subject1700000000000000
Withdrew: Physician decision300000000000000
Withdrew: Pregnancy100000000000000
Injection Phase
Participant flow — Injection Phase
MilestoneOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Started018291132182121298101
Completed01829113217211129851
Not completed000000010100050
Withdrew: Physician decision000000000100000
Withdrew: Withdrawal by subject000000010000050
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Started01829113217211129851
Completed01818112117210108651
Not completed001101100121200
Withdrew: Lost to follow-up000000000021100
Withdrew: Withdrawal by subject001101100100100

Outcome measures

PrimaryPart 1 Injection 1: Time of Maximum Observed Plasma Concentration (Tmax) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h

Blood samples were collected for Pharmacokinetic (PK) analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 1 - Day 1 to Week 4
Reported as:
Mean · Hour (h)
Part 1 Injection 1: Time of Maximum Observed Plasma Concentration (Tmax) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h
Hour (h)Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20
Injection 1197.731 ± 119.0789150.215 ± 27.9825122.009 ± 36.4273145.648 ± 42.1305206.228 ± 100.3655137.853 ± 31.0810131.833 ± 31.3543
Injection 1 [1]——132.575 ± 16.1574————
PrimaryPart 1 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b

Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Day 1 to Week 52 follow-up
Reported as:
Mean · Hour (h)
Part 1 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b
Hour (h)Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)
Part 1 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b135.231 ± 39.8828111.656 ± 36.9740108.305 ± 25.7239147.029 ± 35.9930144.092 ± 89.0230155.350 ± 45.5842
PrimaryPart 2 Injection 1: Tmax for CAB 400 mg/ml Formulation for Cohort 5

Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 1 - Day 1 to Week 12
Reported as:
Mean · Hour (h)
Part 2 Injection 1: Tmax for CAB 400 mg/ml Formulation for Cohort 5
Hour (h)Part 2: Cohort 5 (C5) CAB400
Part 2 Injection 1: Tmax for CAB 400 mg/ml Formulation for Cohort 5163.093 ± 21.7123
PrimaryPart 2 Injection 2: Tmax for CAB 400 mg/ml Formulation for Cohort 5

Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Day 1 to Week 52 follow-up

No measurements were reported for this outcome.

PrimaryPart 1 Injection 2: Apparent Terminal Phase Half-life (T1/2) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Week 4 to Week 52 follow-up
Reported as:
Geometric mean · Hour (h)
Part 1 Injection 2: Apparent Terminal Phase Half-life (T1/2) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b
Hour (h)Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)
Part 1 Injection 2: Apparent Terminal Phase Half-life (T1/2) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b451.4 ± 58.4333.8 ± 51.1375.1 ± 120.6628.8 ± 84.72886 ± 42.0645.0 ± 45.9
PrimaryPart 2 Injection 2: T1/2 for CAB 400 mg/ml Formulation for Cohort 5

Blood samples were collected for PK analysis of CAB after intramuscular (IM) administration. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Week 12 to Week 52 follow-up

No measurements were reported for this outcome.

PrimaryPart 1 Injection 2: Terminal Absorption Elimination Rate Constant (KALA) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b

KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Week 4 to Week 52 follow-up
Reported as:
Geometric mean · 1/h
Part 1 Injection 2: Terminal Absorption Elimination Rate Constant (KALA) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b
1/hPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)
Part 1 Injection 2: Terminal Absorption Elimination Rate Constant (KALA) for CAB 400 mg/ml Formulation for Cohorts 1,2,3,4 & 4b0.001535 ± 58.40.002076 ± 51.10.001847 ± 120.60.001101 ± 84.90.001376 ± 94.30.001074 ± 45.9
PrimaryPart 2 Injection 2: KALA for CAB 400 mg/ml Formulation for Cohort 5

KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected at indicated time points. PK parameters were determined using standard non-compartmental methods. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Week 12 to Week 52 follow-up

No measurements were reported for this outcome.

PrimaryPart 1 Injection 1: Plasma Trough Concentrations (Ctau) of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h

Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.

Time frame:
Injection 1 - Day 1 to Week 4
Reported as:
Geometric mean · Microgram/ millilitre (μg/mL)
Part 1 Injection 1: Plasma Trough Concentrations (Ctau) of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b & 4h
Microgram/ millilitre (μg/mL)Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20ATLAS /FLAIR: Historical Data of CAB200
Injection 12.528 ± 35.11.907 ± 34.51.490 ± 176.61.295 ± 28.61.220 ± 30.70.8572 ± 46.61.371 ± 43.51.382 ± 71.7406
Injection 1 [1]——0.8502 ± 13.0—————
Statistical analysis
  • Part 1: Cohort 1 (C1) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.83 · 90% CI 1.57 to 2.14Geometric Mean Ratio comparing Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400) versus (vs.) ATLAS /FLAIR: Historical data of CAB200
  • Part 1: Cohort 2 (C2) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.38 · 90% CI 1.05 to 1.82Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. ATLAS /FLAIR: Historical data of CAB200
  • Part 1: Cohort 3 (C3) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.08 · 90% CI 0.52 to 2.26Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. ATLAS /FLAIR: Historical data of CAB200
  • Part 1: Cohort 4 (C4) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.41 · 90% CI 1.24 to 1.59Geometric mean ratio comparing Part 1: Cohort 4 (C4) CAB400 vs. ATLAS /FLAIR: Historical data of CAB200 (data for ATLAS /FLAIR: Historical data of CAB200 has been dose normalized to 400 mg).
  • Part 1: Cohort 4b Group 1 (C4b G1) vs Part 1: Cohort 4b Group 2 (C4b G2) vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.48 · 90% CI 1.25 to 1.74Geometric mean ratio comparing C4b CAB400 + Topical Steroid or NSAID (pooled injection 1 data for Part 1: Cohort 4b Group 1 (C4b G1) and Part 1: Cohort 4b Group 2 (C4b G2)) vs. ATLAS /FLAIR: Historical data of CAB200
  • Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.49 · 90% CI 1.12 to 1.97Geometric mean ratio comparing Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 vs. ATLAS /FLAIR: Historical data of CAB200 (data for ATLAS /FLAIR: Historical data of CAB200 has been dose normalized to 400 mg).
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 2 (C2) CAB400 · Geometric mean ratio: 0.75 · 90% CI 0.56 to 1.01Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 0.59 · 90% CI 0.28 to 1.24Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
  • Part 1: Cohort 2 (C2) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 1.28 · 90% CI 0.60 to 2.74Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. Part 1: Cohort 3 (C3) CAB400
  • Part 1: Cohort 4 (C4) CAB400 vs Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 · Geometric mean ratio: 1.06 · 90% CI 0.79 to 1.42Geometric mean ratio comparing Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 vs. Part 1: Cohort 4 (C4) CAB400
PrimaryPart 1 Injection 2: Ctau of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b

Blood samples were collected for PK analysis of CAB. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR studies.

Time frame:
Injection 2 - Day 1 to Week 4
Reported as:
Geometric mean · μg/mL
Part 1 Injection 2: Ctau of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b
μg/mLPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)ATLAS /FLAIR: Historical Data of CAB200
Part 1 Injection 2: Ctau of CAB 400 mg/ml Formulation for Cohorts 1,2,3,4, 4b2.853 ± 40.01.333 ± 60.41.542 ± 51.61.290 ± 31.01.590 ± 26.91.646 ± 34.81.840 ± 49.3234
Statistical analysis
  • Part 1: Cohort 1 (C1) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.55 · 90% CI 1.31 to 1.84Geometric mean ratio comparing Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400) vs. ATLAS /FLAIR: Historical data of CAB200
  • Part 1: Cohort 2 (C2) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.45 · 90% CI 1.00 to 2.11Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. ATLAS /FLAIR: Historical data of CAB200 (data for ATLAS /FLAIR: Historical data of CAB200 has been dose normalized to 200 mg).
  • Part 1: Cohort 3 (C3) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 0.84 · 90% CI 0.63 to 1.11Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs ATLAS /FLAIR: Historical data of CAB200
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 0.57 · 90% CI 0.40 to 0.79Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
PrimaryPart 2 Injection 1: Ctau of CAB 400 mg/ml Formulation for Cohort 5

Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods. Ctau is the trough concentration at the end of the dosing interval. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 800mg was presented. The objective of this endpoint was to analyze and compare the data for participants that received CAB 400 mg/ml formulation in this study, and historical data for CAB 200 mg/mL in ATLAS /FLAIR and ECLAIRE studies.

Time frame:
Injection 1 - Day 1 to Week 12
Reported as:
Geometric mean · μg/mL
Part 2 Injection 1: Ctau of CAB 400 mg/ml Formulation for Cohort 5
μg/mLPart 2: Cohort 5 (C5) CAB400ATLAS /FLAIR: Historical Data of CAB200ÉCLAIR: Historical Data of CAB200
Part 2 Injection 1: Ctau of CAB 400 mg/ml Formulation for Cohort 50.3787 ± 79.71.843 ± 71.74060.3024 ± 157.1133
Statistical analysis
  • Part 2: Cohort 5 (C5) CAB400 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 0.21 · 90% CI 0.13 to 0.32Geometric mean ratio comparing Part 2: Cohort 5 (C5) CAB400 vs. ATLAS /FLAIR: Historical data of CAB200 (data for ATLAS /FLAIR: Historical data of CAB200 has been dose normalized to 800 mg).
  • Part 2: Cohort 5 (C5) CAB400 vs ÉCLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.25 · 90% CI 0.78 to 2.00Geometric mean ratio comparing Part 2: Cohort 5 (C5) CAB400 vs. ÉCLAIR: : Historical data of CAB200
PrimaryPart 1 Injection 1: Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC(0-t)) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h

Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 1 - Day 1 to Week 4
Reported as:
Geometric mean · h*μg/mL
Part 1 Injection 1: Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC(0-t)) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h
h*μg/mLPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20
Injection 12734 ± 27.02640 ± 30.22261 ± 69.91510 ± 42.91142 ± 44.0945.2 ± 29.13133 ± 18.4
Injection 1 [1]——1583 ± 10.4————
Statistical analysis
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 2 (C2) CAB400 · Geometric mean ratio: 1.11 · 90% CI 0.85 to 1.46Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 1.03 · 90% CI 0.77 to 1.40Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
  • Part 1: Cohort 2 (C2) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 1.08 · 90% CI 0.76 to 1.54Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. Part 1: Cohort 3 (C3) CAB400
  • Part 1: Cohort 4 (C4) CAB400 vs Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 · Geometric mean ratio: 1.81 · 90% CI 1.50 to 2.19Geometric mean ratio comparing Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 vs. Part 1: Cohort 4 (C4) CAB400
PrimaryPart 1 Injection 2: AUC(0-t) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4 and 4b

Blood samples were collected for PK analysis of CAB. The PK parameters were calculated by non-compartmental analysis. The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Day 1 to Week 4
Reported as:
Geometric mean · h*μg/mL
Part 1 Injection 2: AUC(0-t) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4 and 4b
h*μg/mLPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)
Part 1 Injection 2: AUC(0-t) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4 and 4b4731 ± 29.32050 ± 51.63170 ± 33.52417 ± 30.92409 ± 27.02649 ± 24.9
Statistical analysis
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 0.73 · 90% CI 0.50 to 1.06Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
PrimaryPart 1 Injection 1: Maximum Observed Plasma Concentration (Cmax) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h

The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 1 - Day 1 to Week 4
Reported as:
Geometric mean · μg/mL
Part 1 Injection 1: Maximum Observed Plasma Concentration (Cmax) of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b and 4h
μg/mLPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20
Injection 16.507 ± 28.76.760 ± 37.76.743 ± 75.13.873 ± 57.02.750 ± 49.62.495 ± 28.38.400 ± 18.4
Injection 1 [1]——6.541 ± 7.6————
Statistical analysis
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 2 (C2) CAB400 · Geometric mean ratio: 1.04 · 90% CI 0.80 to 1.35Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 1.04 · 90% CI 0.71 to 1.51Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
  • Part 1: Cohort 2 (C2) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 1.00 · 90% CI 0.66 to 1.52Geometric mean ratio comparing Part 1: Cohort 2 (C2) CAB400 vs. Part 1: Cohort 3 (C3) CAB400
  • Part 1: Cohort 4 (C4) CAB400 vs Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 · Geometric mean ratio: 2.17 · 90% CI 1.70 to 2.76Geometric mean ratio comparing Part 1: Cohort 4h (C4h) CAB400 + rHuPH20 vs. Part 1: Cohort 4 (C4) CAB400
PrimaryPart 1 Injection 2: Cmax of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b

The objective of this endpoint was to analyze data for participants that received CAB 400 mg/ml formulation, therefore results are presented for those groups only.

Time frame:
Injection 2 - Day 1 to Week 4
Reported as:
Geometric mean · μg/mL
Part 1 Injection 2: Cmax of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b
μg/mLPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)
Part 1 Injection 2: Cmax of CAB 400 mg/ml Formulation for Cohorts 1, 2, 3, 4, 4b7.095 ± 25.83.538 ± 51.65.873 ± 75.33.074 ± 23.83.718 ± 31.43.312 ± 36.2
Statistical analysis
  • Part 1: Cohort 1 (C1) CAB400 vs Part 1: Cohort 3 (C3) CAB400 · Geometric mean ratio: 0.82 · 90% CI 0.52 to 1.28Geometric mean ratio comparing Part 1: Cohort 3 (C3) CAB400 vs. Part 1: Cohort 1 (C1) Cabotegravir 400 (CAB400)
SecondaryPart 1 and Part 2: Number of Participants With Adverse Events (AEs) in Injection Phase and Follow up Phase

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.

Time frame:
From Injection 1 day 1 up to 52 weeks follow-up
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Adverse Events (AEs) in Injection Phase and Follow up Phase
ParticipantsPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400
Injection 1179111812129810
Injection 1 [1]——2——————
Injection 215810161211———
Follow-up325923331
SecondaryPart 1 and Part 2: Number of Participants With Liver Biochemistry Abnormalities in Injection Phase and Follow up Phase

Blood samples were collected at indicated timepoints to analyze the liver biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Bilirubin and Direct Bilirubin. The objective of this analysis is to present the data for participants that received at least an intramuscular or subcutaneous study injection of CAB 400 mg/mL or CAB 200 mg/mL with rHuPH20 formulation.

Time frame:
From Injection 1 day 1 up to 52 weeks follow-up
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Liver Biochemistry Abnormalities in Injection Phase and Follow up Phase
ParticipantsPart 1: Cohort 1 (C1) CAB400Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400
ALT, Injection 1010000020
ALT, Injection 1 [1]——0——————
ALT, Injection 2001000———
ALT, Follow-up211000200
ALP, Injection 1000000000
ALP, Injection 1 [1]——0——————
ALP, Injection 2000000———
ALP, Follow-up000000000
AST, Injection 1010002001
AST, Injection 1 [1]——0——————
AST, Injection 2101000———
AST, Follow-up101200210
Bilirubin, Injection 1000010000
Bilirubin, Injection 1 [1]——0——————
Bilirubin, Injection 2000010———
Bilirubin, Follow-up110200000
Direct Bilirubin, Injection 1000110101
Direct Bilirubin, Injection 1 [1]——0——————
Direct Bilirubin, Injection 2000210———
Direct Bilirubin, Follow-up110100000
SecondaryCmax for CAB Following Oral 30 mg Administration

Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.

Time frame:
Up to Day 29
Reported as:
Geometric mean · μg/mL
Cmax for CAB Following Oral 30 mg Administration
μg/mLOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Cmax for CAB Following Oral 30 mg Administration3.728 ± 19.63.921 ± 15.35.007 ± 8.14.526 ± 18.04.090 ± NA3.573 ± 20.63.841 ± 6.13.864 ± 20.12.863 ± 26.03.428 ± 29.23.975 ± 27.03.393 ± 41.93.929 ± 23.43.243 ± 53.84.030 ± NA
SecondaryTmax for CAB Following Oral 30 mg Administration

Blood samples were collected for PK analysis of CAB. PK parameter was determined using standard non-compartmental methods.

Time frame:
Up to Day 29
Reported as:
Geometric mean · Hour (h)
Tmax for CAB Following Oral 30 mg Administration
Hour (h)Oral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Tmax for CAB Following Oral 30 mg Administration1.9 ± 81.82.031 ± 58.91.000 ± NA1.957 ± 54.11.000 ± NA1.692 ± 67.62.000 ± 127.02.010 ± 54.11.732 ± 91.02.982 ± 58.31.528 ± 51.11.937 ± 55.72.113 ± 57.82.179 ± 78.01.067 ± NA
SecondaryAUC(0-t) for CAB Following Oral 30 mg Administration

Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.

Time frame:
Up to Day 29
Reported as:
Geometric mean · h*μg/mL
AUC(0-t) for CAB Following Oral 30 mg Administration
h*μg/mLOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
AUC(0-t) for CAB Following Oral 30 mg Administration50.725 ± 18.160.91 ± 19.769.29 ± 1.770.31 ± 17.260.62 ± NA56.03 ± 20.058.10 ± 9.358.52 ± 18.946.34 ± 26.457.42 ± 20.759.33 ± 26.552.36 ± 43.563.58 ± 22.845.79 ± 54.257.61 ± NA
SecondaryConcentration at 24 Hours (C24) for CAB Following Oral 30 mg Administration
Time frame:
At 24 hours
Reported as:
Geometric mean · μg/mL
Concentration at 24 Hours (C24) for CAB Following Oral 30 mg Administration
μg/mLOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20
Concentration at 24 Hours (C24) for CAB Following Oral 30 mg Administration1.5450422 ± 19.31.971 ± 20.62.125 ± 1.02.229 ± 16.71.760 ± NA1.748 ± 25.41.744 ± 5.31.808 ± 25.31.489 ± 12.92.059 ± 19.22.001 ± 39.21.671 ± 41.12.033 ± 25.8
SecondaryCtau for CAB Following Oral 30 mg Administration
Time frame:
Up to 24 hours on day 29 (Oral lead in phase)
Reported as:
Geometric mean · μg/mL
Ctau for CAB Following Oral 30 mg Administration
μg/mLOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Ctau for CAB Following Oral 30 mg Administration5.0488137 ± 49.63.629 ± 158.1—3.074 ± 366.62.230 ± NA5.456 ± 42.23.576 ± 23.75.430 ± 44.34.468 ± 3.84.169 ± 76.04.667 ± 31.94.811 ± 51.16.966 ± 59.33.596 ± 60.5—
SecondaryCmax of CAB 200 for Cohort 4h

Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.

Time frame:
Injection 1 - Day 1 to Week 52 follow-up
Reported as:
Geometric mean · μg/mL
Cmax of CAB 200 for Cohort 4h
μg/mLPart 1: Cohort 4h (C4h) CAB200 + rHuPH20
Cmax of CAB 200 for Cohort 4h2.507 ± 29.9
SecondaryTmax of CAB 200 for Cohort 4h

Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameter was determined using standard non-compartmental methods.

Time frame:
Injection 1 - Day 1 to Week 52 follow-up
Reported as:
Geometric mean · Hour (h)
Tmax of CAB 200 for Cohort 4h
Hour (h)Part 1: Cohort 4h (C4h) CAB200 + rHuPH20
Tmax of CAB 200 for Cohort 4h175.064 ± 41.1
SecondaryAUC(0-t) of CAB 200 for Cohort 4h

Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.

Time frame:
Injection 1 - Day 1 to Week 52 follow-up
Reported as:
Geometric mean · h*μg/mL
AUC(0-t) of CAB 200 for Cohort 4h
h*μg/mLPart 1: Cohort 4h (C4h) CAB200 + rHuPH20
AUC(0-t) of CAB 200 for Cohort 4h3087 ± 13.8
SecondaryCtau of CAB 200 for Cohort 4h and in ATLAS/FLAIR Study

Blood samples were collected for PK analysis of CAB after subcutaneous administration. Ctau is the trough concentration at the end of the dosing interval. PK parameter was determined using standard non-compartmental methods. Ctau was expressed as geometric mean. For ATLAS /FLAIR: Historical data of CAB200 group, the geometric mean following dose normalization to 400mg was presented.

Time frame:
Injection 1 - Day 1 to Week 52 follow-up
Reported as:
Geometric mean · μg/mL
Ctau of CAB 200 for Cohort 4h and in ATLAS/FLAIR Study
μg/mLPart 1: Cohort 4h (C4h) CAB200 + rHuPH20ATLAS /FLAIR: Historical Data of CAB200
Ctau of CAB 200 for Cohort 4h and in ATLAS/FLAIR Study1.008 ± 36.60.9216 ± 71.7406
Statistical analysis
  • Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 vs ATLAS /FLAIR: Historical Data of CAB200 · Geometric mean ratio: 1.09 · 90% CI 0.86 to 1.39Geometric mean ratio comparing Part 1: Cohort 4h (C4h) CAB200 + rHuPH20 vs. ATLAS /FLAIR: Historical data of CAB200 (data for ATLAS /FLAIR: Historical data of CAB200 has been dose normalized to 400 mg).
SecondaryT1/2 of CAB 200 & CAB 400 for Cohort 4h

Blood samples were collected for PK analysis of CAB after subcutaneous administration. The PK parameters were calculated by non-compartmental analysis.

Time frame:
Injection 1 - Day 1 to Week 52 follow-up
Reported as:
Geometric mean · Hour (h)
T1/2 of CAB 200 & CAB 400 for Cohort 4h
Hour (h)Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 1: Cohort 4h (C4h) CAB400 + rHuPH20
T1/2 of CAB 200 & CAB 400 for Cohort 4h1233 ± 20.6210.8 ± 42.0
SecondaryKALA of CAB 200 & CAB 400 for Cohort 4h

KALA defined as the rate at which a drug is absorbed into the bloodstream after administration. Blood samples were collected for PK analysis of CAB after subcutaneous administration. PK parameters were determined using standard non-compartmental methods.

Time frame:
Injection 1 - Day 1 to Week 52 follow-up
Reported as:
Geometric mean · 1/h
KALA of CAB 200 & CAB 400 for Cohort 4h
1/hPart 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 1: Cohort 4h (C4h) CAB400 + rHuPH20
KALA of CAB 200 & CAB 400 for Cohort 4h0.0005615 ± 20.60.003288 ± 42.0

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 of OLI Phase up to approximately Week 52 of Follow-up Phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Cabotegravir (CAB) 300/13 (0%)0/13 (0%)4/13 (30.8%)
Part 1: Cohort 1 (C1) CAB4000/18 (0%)0/18 (0%)18/18 (100%)
Part 1: Cohort 1 (C1) CAB2000/2 (0%)0/2 (0%)2/2 (100%)
Part 1: Cohort 2 (C2) CAB4000/11 (0%)0/11 (0%)10/11 (90.9%)
Part 1: Cohort 2 (C2) CAB2000/1 (0%)0/1 (0%)1/1 (100%)
Part 1: Cohort 3 (C3) CAB4000/16 (0%)2/16 (12.5%)15/16 (93.8%)
Part 1: Cohort 3 (C3) CAB2000/2 (0%)0/2 (0%)2/2 (100%)
Part 1: Cohort 4 (C4) CAB4000/18 (0%)0/18 (0%)18/18 (100%)
Part 1: Cohort 4 (C4) CAB2000/2 (0%)0/2 (0%)1/2 (50%)
Part 1: Cohort 4b Group 1 (C4b G1)0/13 (0%)0/13 (0%)13/13 (100%)
Part 1: Cohort 4b Group 2 (C4b G2)0/14 (0%)1/14 (7.1%)13/14 (92.9%)
Part 1: Cohort 4h (C4h) CAB400 + rHuPH200/9 (0%)0/9 (0%)9/9 (100%)
Part 1: Cohort 4h (C4h) CAB200 + rHuPH200/8 (0%)0/8 (0%)8/8 (100%)
Part 2: Cohort 5 (C5) CAB4000/10 (0%)0/10 (0%)10/10 (100%)
Part 2: Cohort 5 (C5) CAB2000/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Hiatus herniaGastrointestinal disorders0/130/180/20/110/10/160/20/180/20/131/140/90/80/100/1
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/130/180/20/110/11/160/20/180/20/130/140/90/80/100/1
AnxietyPsychiatric disorders0/130/180/20/110/11/160/20/180/20/130/140/90/80/100/1
Most frequent other events
Showing 10 of 130
Most frequent other events
EventOral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200
Injection site painGeneral disorders0/1318/182/28/111/112/162/217/181/212/1312/149/98/810/101/1
Injection site noduleGeneral disorders0/1310/180/24/111/11/160/29/180/27/135/142/90/82/101/1
Injection site erythemaGeneral disorders0/138/181/28/110/14/161/218/181/212/1312/149/98/84/100/1
Injection site indurationGeneral disorders0/136/180/25/110/13/162/28/181/23/132/140/91/80/100/1
Injection site haemorrhageGeneral disorders0/130/180/21/111/10/160/20/180/20/130/140/90/80/100/1
White blood cell count increasedInvestigations0/130/180/20/110/10/160/21/180/20/130/141/90/80/101/1
AccidentInjury, poisoning and procedural complications0/130/180/20/110/10/160/20/180/20/130/140/90/80/101/1
Injection site warmthGeneral disorders0/135/180/22/110/13/160/210/180/212/1311/148/96/86/100/1
Injection site swellingGeneral disorders0/132/180/24/110/16/160/210/180/210/139/147/97/87/100/1
Injection site pruritusGeneral disorders0/131/180/25/110/14/160/26/180/27/135/147/97/80/100/1

Baseline characteristics

Age, Customized
Age, Customized(Participants)Oral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200Total
Adult (18-64 years)13182111162182131498101138
Sex: Female, Male
Sex: Female, Male(Participants)Oral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200Total
Female712130619155462062
Male661811019189528176
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral Cabotegravir (CAB) 30Part 1: Cohort 1 (C1) CAB400Part 1: Cohort 1 (C1) CAB200Part 1: Cohort 2 (C2) CAB400Part 1: Cohort 2 (C2) CAB200Part 1: Cohort 3 (C3) CAB400Part 1: Cohort 3 (C3) CAB200Part 1: Cohort 4 (C4) CAB400Part 1: Cohort 4 (C4) CAB200Part 1: Cohort 4b Group 1 (C4b G1)Part 1: Cohort 4b Group 2 (C4b G2)Part 1: Cohort 4h (C4h) CAB400 + rHuPH20Part 1: Cohort 4h (C4h) CAB200 + rHuPH20Part 2: Cohort 5 (C5) CAB400Part 2: Cohort 5 (C5) CAB200Total
De-identified11172111162151121388101128
Other, unspecified21000003111100010
08

Study locations

5 sites
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
  • GSK Investigational Site
    Berlin, New Jersey 08009, United States
  • GSK Investigational Site
    Austin, Texas 78744, United States
  • GSK Investigational Site
    Auckland, 1010, New Zealand
09

References and documents

Publications

  • Han K, Benn P, Sievers J, Dorey D, Warwick-Sanders M, Hareedy R, Harkness L, Leemereise C, Offenbecker K, Donatti C, Brimhall DB, Schwabe C, Boyle C, Hassman MA, Knowles S, D'Amico R, Spreen WR. A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV. Clin Pharmacol Drug Dev. 2025 Jul;14(7):528-541. doi: 10.1002/cpdd.1538. Epub 2025 Apr 29. PubMed 40296638 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2023, 33 months.

Results were first posted in May 2026, 3 years after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 33 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 23, 2020
StartActual
Jul 31, 2020
Primary completionActual
May 5, 2023
CompletionActual
May 5, 2023
Results first posted
May 29, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04484337
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jul 23, 2020
Start date
Jul 31, 2020
Primary completion
May 5, 2023
Completion
May 5, 2023
Results posted
May 29, 2026
Last update
May 29, 2026

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion